News
01-29-2010, 10:50 PM
The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.
More... (http://www.news-medical.net/news/20100130/FDA-approves-new-drug-combination-for-hormone-positive-and-HER2-positive-advanced-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20100130/FDA-approves-new-drug-combination-for-hormone-positive-and-HER2-positive-advanced-breast-cancer.aspx)